Explore the latest in pneumonia, including advances in understanding the microbiology and optimal treatment of community-acquired and nosocomial infection.
This randomized clinical trial evaluates the efficacy of convalescent plasma plus standard therapy vs standard care alone in preventing worsening respiratory failure or death in patients with COVID-19 pneumonia.
This randomized clinical trial compares the need for re-treatment of respiratory infection following hospitalization for community-acquired pneumonia among children receiving amoxicillin at high doses vs low doses and at 3-days vs 7-days duration.
This secondary analysis of a randomized clinical trial assesses treatment failure risk factors in patients with community-acquired pneumonia who reached clinical stability after 3 days of β-lactam treatment.
This cohort study examines serum ferritin levels as a potential biomarker associated with response to methylprednisolone among nonintubated patients with severe COVID-19 pneumonia.
This clinical trial assessed whether Lactobacillus rhamnosus GG compared with placebo reduces ventilator-associated pneumonia and other clinically important outcomes for a broad range of critically ill patients.
This case-control study examines changes in quality of care at rural hospitals that merged with or were acquired by other hospitals compared with hospitals that remained independent.
This study examines the associations of corticosteroid bursts with severe adverse events, including gastrointestinal bleeding, sepsis, pneumonia, and glaucoma, in children.
This economic evaluation assesses whether solar-powered oxygen delivery is a cost-effective intervention for children younger than 5 years with hypoxemia in low-resource settings.
This comparative effectiveness study uses national Medicare data on hospitalizations to evaluate whether the inclusion of present-on-admission indicators is associated with improved discrimination in Centers for Medicare & Medicaid Services (CMS) hospital quality risk models for 30-day mortality and readmission.
This equivalence and noninferiority randomized clinical trial assesses whether 5 days of high-dose amoxicillin for community-acquired pneumonia was associated with noninferior rates of clinical cure compared with 10 days of high-dose amoxicillin among children 10 years or younger.
This case-control study investigates the association between nasal microbial profiles and odds of infection after elective surgical procedures.
This cohort study characterizes the accuracy of the Sequential Organ Failure Assessment (SOFA) score to discriminate death from survival in patients with COVID-19 pneumonia receiving oxygen therapy for 4 hours or longer before undergoing endotracheal intubation.
This cohort study assesses mortality and readmission rates of adult patients with COVID-19 pneumonia discharged from 2 centers in Los Angeles County, California, via an expected practice approach to home or quarantine housing with supplemental home oxygen.
This cross-sectional study evaluates the appropriateness of antimicrobial use for hospitalized patients treated for community-acquired pneumonia or a urinary tract infection present at admission or for patients who had received fluoroquinolone or intravenous vancomycin treatment.
This cross-sectional study assesses medical records for evidence of racial bias in clinician documentation among patients admitted for breast cancer, sickle cell disease with crisis, status epilepticus, hypertensive emergency, pneumonia, or motor vehicle collision.
This cross-sectional study assesses whether hospitals were incorrectly penalized or incorrectly nonpenalized by the Hospital Readmissions Reduction Program for patient readmissions for acute myocardial infarction, heart failure, and pneumonia.
This cohort study uses data from national registries to examine the association between the receipt of α1–adrenergic receptor blockers and the risks of 30-day mortality and intensive care unit admission among adult patients hospitalized with influenza or pneumonia in Denmark between 2005 and 2018.
Customize your JAMA Network experience by selecting one or more topics from the list below.